Smith & Nephew (LON:SN) Hits New 1-Year High - Here's Why

Smith & Nephew plc (LON:SN - Get Free Report) hit a new 52-week high on Friday . The stock traded as high as GBX 1,250.50 and last traded at GBX 1,248, with a volume of 1196793 shares trading hands. The stock had previously closed at GBX 1,240.50.Get Smith & Nephew alerts:Analyst Ratings ChangesSeveral brokerages have recently commented on SN. Royal Bank Of Canada downgraded Smith & Nephew to a "sector perform" rating and lowered their price objective for the stock from GBX 1,700 to GBX 1,350 in a research note on Wednesday, December 17th. Berenberg Bank reaffirmed a "hold" rating and set a GBX 1,300 target price on shares of Smith & Nephew in a research report on Friday, January 23rd. Finally, Panmure Gordon reiterated a "hold" rating and set a GBX 1,200 price target on shares of Smith & Nephew in a report on Tuesday, December 9th. Two equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of GBX 1,381.33.Read Our Latest Analysis on Smith & NephewSmith & Nephew Price PerformanceThe firm has a market cap of £13.68 billion, a PE ratio of 44.93, a P/E/G ratio of 0.46 and a beta of 0.68. The company has a debt-to-equity ratio of 62.90, a current ratio of 2.57 and a quick ratio of 0.84. The business's fifty day moving average is GBX 1,272.11 and its 200-day moving average is GBX 1,298.93. About Smith & Nephew (Get Free Report)Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.Further ReadingFive stocks we like better than Smith & NephewA personal warning from Martin Weiss (Please read)SpaceX IPO Confirmed: Claim Your Stake TodayIran isn't the real warThis coin has everything going for itOnly 500 people today…This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Smith & Nephew Right Now?Before you consider Smith & Nephew, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew wasn't on the list.While Smith & Nephew currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here